<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01891123</url>
  </required_header>
  <id_info>
    <org_study_id>DT0508</org_study_id>
    <nct_id>NCT01891123</nct_id>
  </id_info>
  <brief_title>Explore the Individual Treatment of Docetaxel and Paclitaxel in NSCLC, NPC and BRC by PK-guided Dosing Strategy</brief_title>
  <official_title>An Open-label Randomized Clinical Trial to Compare the Toxicities and Efficacy of Pharmacokinetically-guided and BSA Fixed Dosing Strategy of Docetaxel and Paclitaxel in Chinese Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, and Breast Cancer Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As cytotoxic agents, DTX and PTX have a narrow therapeutic window. BSA dosing leads to great
      inter-individual PK variability, which is a major contributor for severe toxicity, especially
      in East-Asian populations. DTX exposures measured by area under plasma concentration-time
      curve (AUC), PTX exposures measured by the time above a plasma concentration of 0.05 µmol/L
      (TC&gt;0.05), are the most biologic effects associated PK parameters for DTX and PTX,
      respectively, which could positively predict related toxicities such as neutropenia,
      peripheral neuropathy, etc. So, we conducted a randomized clinical trial to compare the
      effect on related toxicities and efficacy of PK-guided dosing strategy and BSA dosing
      strategy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      3 populations were included: advanced NSCLC patients receive a single-agent docetaxel regimen
      palliative chemotherapy without restriction of lines; NPC patients receive paclitaxel and
      carboplatin doublet regimen whether as induction chemotherapy for local advanced patients or
      palliative chemotherapy for metastatic patients; BRC patients receive a single-agent
      docetaxel regimen after 4 cycles of adriamycin and cyclophosphamide for adjuvant
      chemotherapy. Patients are randomly assigned into the BSA-based dosing group and
      pharmacokinetically-guided dosing group. In the BSA-based dosing group, NPC patients receive
      paclitaxel (175mg/m2) and carboplatin (AUC=5) treatment, NSCLC and BRC patients receive
      docetaxel (75mg/m2) treatment, 3-weekly and for up to 6 cycles. BSA group and PK-guided group
      are with a same starting dose. DTX exposure (AUC) and PTX exposure (TC&gt;0.05) are calculated
      from a published PK model with an established limited sampling strategy. Dose of subsequent
      cycles of PK-guided group patients is calculated base on the previous cycle PK results,
      according to optimal target algorithm. The optimal target for DTX exposure is 2.5 - 3.7
      µg•h/mL. Dose reductions were permitted in both arms according to instructions. The study had
      a power of 80% to detect a 23% reduction of grade &gt;3 neutropenia with PK-guided arm for DTX
      sub-study in NSCLC. A sample size of 100 NSCLC patients was estimated by using Fisher's exact
      test to provide a 5% two-sided alpha significance level to observe a decrease in the
      hematological toxicity with a power of 0.8. This is based on the reported toxicity rates of
      85% with dose of 75mg/m2 and 63% with 60mg/m2. Objective response rate is evaluated by
      imaging examination (CT or MR scan) every 2 cycles. Toxicities are evaluated by patients'
      diary for toxicity reports and physician's evaluation at day 10 and day 21 at every cycle.
      Blood samples are collected every cycle. And survival information is collected by clinic and
      telephone follow-up. Research Hypothesis: 1. The concentrations variability dosed by BSA, and
      the limitation of BSA- and MTD-based dosing. 2. Verify that paclitaxel TC&gt;0.05 and docetaxel
      AUC are the most relevant predictor of related toxicities and clinical outcomes. 3. Verify
      the feasibility of dosing algorithm based on paclitaxel TC&gt;0.05 and docetaxel AUC, quantify
      its effect on both reducing toxicity and improving Effectiveness. 4. The effect of using dose
      modification and administration of G-CSF based on toxicity determined by paclitaxel TC&gt;0.05
      and docetaxel AUC measurement. 5. Prove the ability of PK-guided dosing strategy in reducing
      DTX and PTX related hematologic and non-hematologic toxicities, and the effect on treatment
      efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicities rate</measure>
    <time_frame>3 weeks, 6 weeks, 9 weeks, 12 weeks, 15 weeks, 18weeks</time_frame>
    <description>assess the toxicities rate and severity according to CTCAE v4.03, record the toxicities incident and grades from the first cycle to last cycle until the toxicities relieve or stabilize.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Object response rate</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>assess the ORR according to RECIST v1.1, An imaging examination should be performed in 4weeks before treatment initiation, and patients are going to receive (CT or MR scan) every 2 cycles during the treatment, the methods should be identical with baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival Effectiveness</measure>
    <time_frame>36 months</time_frame>
    <description>after treatment discontinuation, PFS is recorded by imaging examination every 2 cycles (8 weeks) until tumor progression, other anti-cancer treatment start, trial ends or death. OS is recorded by clinic follow-up or telephone follow-up until death.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>the quality of life of patients</measure>
    <time_frame>3 weeks, 6 weeks, 9 weeks, 12 weeks, 15 weeks, 18weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Nasal Cancer</condition>
  <arm_group>
    <arm_group_label>body surface area</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients receive fixed dose of PTX or DOC based on body surface area every cycle, PTX 175mg/m2, DOC 75mg/m2. Patients should finish up to 6 cycles chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Detection Kit</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PTX 175mg/m2, DOC 75mg/m2 at first cycle. the dose of PTX or DOC will adjust based on the pharmacokinetic results of previous cycle. A optimal target of PTX(TC&gt;0.05) and DOC(AUC) have been set from published PK model with an established limited sampling strategy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PK guided arm</intervention_name>
    <description>the dose of PTX or DOC will adjust based on the plasma drug concentration of previous cycle</description>
    <arm_group_label>Detection Kit</arm_group_label>
    <other_name>pharmacokinetic guided dosing stratety</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTX 175mg/m2, DOC 75mg/m2</intervention_name>
    <description>patients receive PTX or DOC dose based on body surface area every cycle, PTX 175mg/m2, DOC 75mg/m2</description>
    <arm_group_label>body surface area</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed by pathology for advanced non small cell lung cancer, suitable for
             paclitaxel or docetaxel chemotherapy (clinical stage IV according to 2009 IASLC
             staging or recurrent NSCLC; receiving palliative chemotherapy independent of lines)

          -  ECOG PS score: 0 to 2 points

          -  Survival is expected to more than 3 month

          -  Bone marrow reserve function is good, the function of organs (liver and kidney) is
             good, can satisfy the conditions of implementation chemotherapy.

          -  Sign the informed consent form

          -  Compliance is good, can be followed up, willing to comply with the requirements of the
             study

        Exclusion Criteria:

          -  Physical status score (ECOG) greater than 2

          -  organic disease；Severely active infection；Organ transplantation immune therapy；Can't
             complete with in four to six cycles of chemotherapy

          -  Bone marrow, liver and kidney dysfunction, clinical doctors identify intolerance to
             chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shu Sen Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>YuXiang Ma</last_name>
    <phone>86-020-87343786</phone>
    <email>mayx@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>GuangZhou</city>
        <state>Guangdong</state>
        <zip>510030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YuXiang Ma</last_name>
      <phone>8602087343786</phone>
      <email>mayx@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer. 2011 Feb;30(2):114-9. Review.</citation>
    <PMID>21272443</PMID>
  </reference>
  <reference>
    <citation>Chan AT, Ma BB, Lo YM, Leung SF, Kwan WH, Hui EP, Mok TS, Kam M, Chan LS, Chiu SK, Yu KH, Cheung KY, Lai K, Lai M, Mo F, Yeo W, King A, Johnson PJ, Teo PM, Zee B. Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. J Clin Oncol. 2004 Aug 1;22(15):3053-60.</citation>
    <PMID>15284255</PMID>
  </reference>
  <reference>
    <citation>Miyaushiro S, Kitanaka A, Kubuki Y, Hidaka T, Shide K, Kameda T, Sekine M, Kamiunten A, Umekita Y, Kawabata T, Ishiguro Y, Shimoda K. Nasopharyngeal carcinoma with bone marrow metastasis: positive response to weekly paclitaxel chemotherapy. Intern Med. 2015;54(11):1455-9. doi: 10.2169/internalmedicine.54.3917. Epub 2015 Jun 1.</citation>
    <PMID>26028007</PMID>
  </reference>
  <reference>
    <citation>Ciuleanu TE, Fountzilas G, Ciuleanu E, Plataniotis M, Todor N, Ghilezan N. Paclitaxel and carboplatin in relapsed or metastatic nasopharyngeal carcinoma: a multicenter phase II study. J BUON. 2004 Apr-Jun;9(2):161-5.</citation>
    <PMID>17415808</PMID>
  </reference>
  <reference>
    <citation>Tan EH, Khoo KS, Wee J, Fong KW, Lee KS, Lee KM, Chua ET, Tan T, Khoo-Tan HS, Yang TL, Au E, Tao M, Ong YK, Chua EJ. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol. 1999 Feb;10(2):235-7.</citation>
    <PMID>10093695</PMID>
  </reference>
  <reference>
    <citation>Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer. 2005 Jun;5(6):447-58. Review.</citation>
    <PMID>15928675</PMID>
  </reference>
  <reference>
    <citation>Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JH, Grochow LB, Sparreboom A. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst. 2002 Dec 18;94(24):1883-8.</citation>
    <PMID>12488482</PMID>
  </reference>
  <reference>
    <citation>Engels FK, Loos WJ, van der Bol JM, de Bruijn P, Mathijssen RH, Verweij J, Mathot RA. Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study. Clin Cancer Res. 2011 Jan 15;17(2):353-62. doi: 10.1158/1078-0432.CCR-10-1636. Epub 2011 Jan 11.</citation>
    <PMID>21224369</PMID>
  </reference>
  <reference>
    <citation>Rudek MA, Sparreboom A, Garrett-Mayer ES, Armstrong DK, Wolff AC, Verweij J, Baker SD. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer. 2004 May;40(8):1170-8.</citation>
    <PMID>15110880</PMID>
  </reference>
  <reference>
    <citation>Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol. 1998 Jan;16(1):187-96.</citation>
    <PMID>9440742</PMID>
  </reference>
  <reference>
    <citation>Rosing H, Lustig V, van Warmerdam LJ, Huizing MT, ten Bokkel Huinink WW, Schellens JH, Rodenhuis S, Bult A, Beijnen JH. Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. Cancer Chemother Pharmacol. 2000;45(3):213-8.</citation>
    <PMID>10663639</PMID>
  </reference>
  <reference>
    <citation>Bruno R, Vivier N, Veyrat-Follet C, Montay G, Rhodes GR. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest New Drugs. 2001 May;19(2):163-9. Review.</citation>
    <PMID>11392450</PMID>
  </reference>
  <reference>
    <citation>Baker SD, Li J, ten Tije AJ, Figg WD, Graveland W, Verweij J, Sparreboom A. Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin Pharmacol Ther. 2005 Jan;77(1):43-53.</citation>
    <PMID>15637530</PMID>
  </reference>
  <reference>
    <citation>Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res. 1993 Mar 1;53(5):1037-42.</citation>
    <PMID>8094996</PMID>
  </reference>
  <reference>
    <citation>Minami H, Kawada K, Sasaki Y, Igarashi T, Saeki T, Tahara M, Itoh K, Fujii H. Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients. Cancer Sci. 2006 Mar;97(3):235-41.</citation>
    <PMID>16542221</PMID>
  </reference>
  <reference>
    <citation>Minami H, Ohe Y, Niho S, Goto K, Ohmatsu H, Kubota K, Kakinuma R, Nishiwaki Y, Nokihara H, Sekine I, Saijo N, Hanada K, Ogata H. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients? J Clin Oncol. 2004 Jul 15;22(14):2901-8.</citation>
    <PMID>15254059</PMID>
  </reference>
  <reference>
    <citation>Minami H, Kawada K, Sasaki Y, Tahara M, Igarashi T, Itoh K, Fujii H, Saeki T, Ozawa K, Sato H. Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Sci. 2009 Jan;100(1):144-9. doi: 10.1111/j.1349-7006.2009.00992.x. Epub 2008 Oct 30.</citation>
    <PMID>19018756</PMID>
  </reference>
  <reference>
    <citation>Ozawa K, Minami H, Sato H. Logistic regression analysis for febrile neutropenia (FN) induced by docetaxel in Japanese cancer patients. Cancer Chemother Pharmacol. 2008 Aug;62(3):551-7. Epub 2007 Dec 7.</citation>
    <PMID>18064462</PMID>
  </reference>
  <reference>
    <citation>Ozawa K, Minami H, Sato H. Clinical trial simulations for dosage optimization of docetaxel in patients with liver dysfunction, based on a log-binominal regression for febrile neutropenia. Yakugaku Zasshi. 2009 Jun;129(6):749-57.</citation>
    <PMID>19483418</PMID>
  </reference>
  <reference>
    <citation>Ghersi D, Wilcken N, Simes RJ. A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer. 2005 Aug 8;93(3):293-301. Review.</citation>
    <PMID>16052223</PMID>
  </reference>
  <reference>
    <citation>Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E 3rd, Schilsky RL, Wood WC, Muss HB, Norton L. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15;21(6):976-83.</citation>
    <PMID>12637460</PMID>
  </reference>
  <reference>
    <citation>Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM; GEICAM 9906 Study Investigators. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. doi: 10.1093/jnci/djn151. Epub 2008 May 27.</citation>
    <PMID>18505968</PMID>
  </reference>
  <reference>
    <citation>Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006 May 1;24(13):2019-27. Epub 2006 Apr 10.</citation>
    <PMID>16606972</PMID>
  </reference>
  <reference>
    <citation>Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA, Meyer WG, Asmar L. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006 Dec 1;24(34):5381-7. Erratum in: J Clin Oncol. 2007 May 1;25(13):1819.</citation>
    <PMID>17135639</PMID>
  </reference>
  <reference>
    <citation>O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002 Jun 15;20(12):2812-23.</citation>
    <PMID>12065558</PMID>
  </reference>
  <reference>
    <citation>Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008 Apr 17;358(16):1663-71. doi: 10.1056/NEJMoa0707056. Erratum in: N Engl J Med. 2009 Apr 16;360(16):1685. N Engl J Med. 2008 Jul 3;359(1):106.</citation>
    <PMID>18420499</PMID>
  </reference>
  <reference>
    <citation>Milano G, Etienne MC, Renée N, Thyss A, Schneider M, Ramaioli A, Demard F. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol. 1994 Jun;12(6):1291-5.</citation>
    <PMID>8201391</PMID>
  </reference>
  <reference>
    <citation>Gambacorti-Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, Bungaro S, Tornaghi L, Rossi F, Pioltelli P, Pogliani E, Alberti D, Corneo G, D'Incalci M. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res. 2003 Feb;9(2):625-32.</citation>
    <PMID>12576428</PMID>
  </reference>
  <reference>
    <citation>Alexandre J, Rey E, Girre V, Grabar S, Tran A, Montheil V, Rabillon F, Dieras V, Jullien V, Hérait P, Pons G, Treluyer JM, Goldwasser F. Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. Ann Oncol. 2007 Jan;18(1):168-72. Epub 2006 Oct 23.</citation>
    <PMID>17060489</PMID>
  </reference>
  <reference>
    <citation>Huizing MT, Keung AC, Rosing H, van der Kuij V, ten Bokkel Huinink WW, Mandjes IM, Dubbelman AC, Pinedo HM, Beijnen JH. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol. 1993 Nov;11(11):2127-35.</citation>
    <PMID>7901342</PMID>
  </reference>
  <reference>
    <citation>Sarosy G, Reed E. Taxol dose intensification and its clinical implications. J Natl Med Assoc. 1993 Jun;85(6):427-31. Review.</citation>
    <PMID>8103561</PMID>
  </reference>
  <reference>
    <citation>Huizing MT, Giaccone G, van Warmerdam LJ, Rosing H, Bakker PJ, Vermorken JB, Postmus PE, van Zandwijk N, Koolen MG, ten Bokkel Huinink WW, van der Vijgh WJ, Bierhorst FJ, Lai A, Dalesio O, Pinedo HM, Veenhof CH, Beijnen JH. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J Clin Oncol. 1997 Jan;15(1):317-29.</citation>
    <PMID>8996159</PMID>
  </reference>
  <reference>
    <citation>Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Calvert H, Boddy AV, Hollema H, Féty R, Van der Vijgh WJ, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers AH, Twelves C, Beijnen JH, Schellens JH. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res. 2007 Nov 1;13(21):6410-8.</citation>
    <PMID>17975154</PMID>
  </reference>
  <reference>
    <citation>Miller AA, Rosner GL, Egorin MJ, Hollis D, Lichtman SM, Ratain MJ. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763. Clin Cancer Res. 2004 Dec 15;10(24):8325-31.</citation>
    <PMID>15623609</PMID>
  </reference>
  <reference>
    <citation>Ohtsu T, Sasaki Y, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y, Saijo N. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res. 1995 Jun;1(6):599-606.</citation>
    <PMID>9816021</PMID>
  </reference>
  <reference>
    <citation>Gianni L, Kearns CM, Giani A, Capri G, Viganó L, Lacatelli A, Bonadonna G, Egorin MJ. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol. 1995 Jan;13(1):180-90.</citation>
    <PMID>7799018</PMID>
  </reference>
  <reference>
    <citation>Jiko M, Yano I, Sato E, Takahashi K, Motohashi H, Masuda S, Okuda M, Ito N, Nakamura E, Segawa T, Kamoto T, Ogawa O, Inui K. Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. Int J Clin Oncol. 2007 Aug;12(4):284-90. Epub 2007 Aug 20.</citation>
    <PMID>17701008</PMID>
  </reference>
  <reference>
    <citation>Mielke S, Sparreboom A, Steinberg SM, Gelderblom H, Unger C, Behringer D, Mross K. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res. 2005 Jul 1;11(13):4843-50.</citation>
    <PMID>16000582</PMID>
  </reference>
  <reference>
    <citation>Joerger M, Huitema AD, van den Bongard DH, Schellens JH, Beijnen JH. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2150-7.</citation>
    <PMID>16609028</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2013</study_first_submitted>
  <study_first_submitted_qc>July 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2013</study_first_posted>
  <last_update_submitted>December 8, 2015</last_update_submitted>
  <last_update_submitted_qc>December 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Li Zhang</investigator_full_name>
    <investigator_title>Profressor</investigator_title>
  </responsible_party>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>plasma drug concentration</keyword>
  <keyword>Nasopharygeal carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Nose Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

